TITLE:
Notoginsenoside R1 Attenuates Hypoxia and Hypercapnia-Induced Vasoconstriction In Vitro by Reducing the Expression of p38
AUTHORS:
Congcong Zhang, Meiping Zhao, Mengxiao Zheng, Longsheng Song, Wantie Wang
KEYWORDS:
Hypoxic Hypercapnia, p38 MAPK, Notoginsenoside R1, Pulmonary Arterial Smooth Muscle Cells
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.5 No.8,
August
2,
2017
ABSTRACT: Notoginsenoside R1, the main
active ingredient of Panax notoginseng saponins (PNS), has been proposed to
play fatal roles in the development of hypoxic hypercapnia-induced pulmonary
vasoconstriction (HHPV). Subsequently, pulmonary arterial smooth muscle cells (PASMCs) lead to pulmonary
vascular system remodeling and chronic pulmonary disease in the development of
HHPV. Despite considerable studies have contributed to pulmonary disease, the
mechanism of how Notoginsenoside R1 affects HHPV remains unclear. In this
view, we will discuss the effect of notoginsenoside R1 by
investigating the expression of p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway in
PASMCs under hypoxia and hypercapnia condition. The third order PASMCs of
Sprague Dawley (SD) rats were cultured with various concentrations (8, 40, 100 mg/L, respectively) of
Notoginsenoside R1.
Our data showed that the protein and mRNA expression levels of p-38 MAPK were
higher in hypoxic hypercapnia group compared with hypoxic DMSO and normoxia
control groups (p 1 treatment groups, the
level of p-p38 MAPK protein and p38 MAPK mRNA were significantly decreased with
different degrees (p 1 treatment may contribute to attenuate HHPV via decreasing the protein and mRNA
expression levels of p-38 MAPK.